A 61-year-old man with a history of 2-vessel coronary artery stenting, hypertension and type-2 diabetes mellitus was admitted 5 times within September 2017 and November 2018 for recurrent angina CCS class III-IV refractory to therapy with nitrates, b-blockers and ranolazine in maximally tolerated doses...

Paris, France, 22 May 2019. Identification and management of patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI) is of major importance, but a lack of standardisation in defining this population limits trial design, data interpretation, and clinical decision-making.

Panos Xaplanteris provides his take on WATCH-TAVR results which were presented by Samir R. Kapadia at TCT Congress 2023.

Safety and Efficacy of Left Atrial Appendage Occlusion at the Time of Transcatheter Aortic Valve Replacement - The WATCH TAVR Trial

Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.

The results of the SCOPE I trial were presented at TCT 2019 in San Francisco by Jonas Lanz, Bern University Hospital. Read the analysis by Fabien Praz.

Paris, France, 24 May 2019. A total of 11,206 participants from over 120 different countries were present at the 30th edition of EuroPCR. An additional 4,700 online learners connected to watch a selection of sessions that were made available both live and on replay via PCR...

Kalaivani Mahadevan provides her take on the five-year outcomes of the FAME 3 trial presented by William F. Fearon at ACC.25 in Chicago.

Daniele Giacoppo analyses the main results of the FLAVOUR trial which were presented by Bon-Kwon Koo, from Seoul National University Hospital, South Korea at the American College of Cardiology 2022.